BRIEF REPORT - TREATMENT OF ADULT T-CELL LEUKEMIA-LYMPHOMA WITH ZIDOVUDINE AND INTERFERON-ALFA

被引：198

作者：

HERMINE, O

BOUSCARY, D

GESSAIN, A

TURLURE, P

LEBLOND, V

FRANCK, N

BUZYNVEIL, A

RIO, B

MACINTYRE, E

DREYFUS, F

BAZARBACHI, A

机构：

[1] HOP NECKER ENFANTS MALAD,DEPT BIOL HEMATOL,F-75743 PARIS 15,FRANCE

[2] HOP COCHIN,DEPT CLIN HEMATOL,F-75674 PARIS,FRANCE

[3] HOP COCHIN,DEPT DERMATOL,F-75674 PARIS,FRANCE

[4] INST PASTEUR,DEPT RETROVIRUSES,PARIS,FRANCE

[5] HOP BEAUJON,DEPT CLIN HEMATOL,CLICHY,FRANCE

[6] HOP PITIE,DEPT CLIN HEMATOL,PARIS,FRANCE

[7] HOP HOTEL DIEU,DEPT CLIN HEMATOL,PARIS,FRANCE

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 1995年 / 332卷 / 26期

关键词：

D O I：

10.1056/NEJM199506293322604

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Human T-cell lymphotropic virus type I (HTLV-I)1 is the etiologic agent of adult T-cell leukemia-lymphoma.2 The serum of patients with this disease contains antibodies to HTLV-I,3 and there is monoclonal integration of HTLV-I proviruses in the malignant cells.4 The principal clinical features of adult T-cell leukemia-lymphoma5 are lymphadenopathy, hepatosplenomegaly, skin lesions, and hypercalcemia. Compromise of the immune system can allow opportunistic infection. The blood contains abnormal lymphocytes with characteristic indented or convoluted nuclei (flower cells). These malignant lymphocytes are activated CD4-positive T cells with increased expression of the alpha chain of the interleukin-2 receptor. Four different clinical subtypes of adult. © 1995, Massachusetts Medical Society. All rights reserved.

引用

页码：1749 / 1751

页数：3

共 22 条

[1]

Poiesz B., Ruscetti F., Gazdar A., Bunn P., Minna J., Gallo R., Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, Proc Natl Acad Sci U S A, 77, pp. 7415-7419, (1980)

[2]

Wong-Staal F., Gallo R., Human T-lymphotropic retroviruses, Nature, 317, pp. 395-403, (1985)

[3]

Hinuma Y., Nagata K., Hanaoka M., Adult T-cell leukaemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera, Proc Natl Acad Sci U S A, 78, pp. 6476-6480, (1981)

[4]

Seiki M., Eddy R., Shows T., Yoshida M., Nonspecific integration of the HTLV provirus genome into adult T-cell leukemia cells, Nature, 309, pp. 640-642, (1984)

[5]

Takatsuki F., Yamaguchi K., Hattori T., Adult T-cell leukemia/lymphoma, pp. 147-159, (1990)

[6]

Shimoyama M., Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87), Br J Haematol, 79, pp. 428-437, (1991)

[7]

Bunn P., Schechter G., Jaffe E., Clinical course of retrovirus-associated adult T-cell lymphoma in the United States, N Engl J Med, 309, pp. 257-264, (1983)

[8]

Shimoyama M., Treatment of patients with adult T-cell leukemia-lymphoma: an overview, Gann Monogr Cancer Res, 39, pp. 43-56, (1992)

[9]

Waldmann T., White J., Goldman C., The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia, Blood, 82, pp. 1701-1712, (1993)

[10]

Matsushima M., Yoneyama A., Nakamura T., A first case of complete remission of beta-interferon sensitive adult T-cell leukemia, Eur J Haematol, 39, pp. 282-287, (1987)

← 1 2 3 →